Status:
UNKNOWN
Assessment of Clinical Onset of IV Heparin in Interventional Cardiology and Cardiac Surgery
Lead Sponsor:
Rhode Island Hospital
Conditions:
Transcatheter Aortic Valve Replacement
Cardiac Valve Annuloplasty
Eligibility:
All Genders
18-90 years
Brief Summary
The efficiency and promptness of heparin anticoagulation is necessary during the structural heart procedures to minimize time from insertion of cannulae to valve deployment in cardiac surgery. The goa...
Detailed Description
Adequate anticoagulation is achieved in cardiac surgery and interventional cardiology procedures with intravenous (IV) administration of unfractionated heparin. The Activated clotting time (ACT) is ro...
Eligibility Criteria
Inclusion
- Adult cardiac surgery patients presenting for elective valvular surgery
- Interventional cardiology patients presenting elective Transcatheter Aortic Valve Replacement (TAVR)
Exclusion
- Preoperative IV heparin administration within 12 hours of surgery
- Preoperative oral anticoagulant use within 24 hours of surgery
- Platelet count \<120,000U/ml within 24 hours of surgery
Key Trial Info
Start Date :
March 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04785885
Start Date
March 9 2021
End Date
April 30 2022
Last Update
September 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rhode Island Hospital
Providence, Rhode Island, United States, 02903